Sorrento surges on antibody ‘shield’ trials for coronavirus

Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in

Epsilogen licenses first-in-class IgE ovarian cancer drug

Regeneron’s Ebola drug heading for October verdict from FDA

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

China’s Adagene raises $69m for cancer immunotherapies

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO